Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

TransMedics (TMDX) Accumulated Depreciation & Amortization (2018 - 2026)

TransMedics has reported Accumulated Depreciation & Amortization over the past 8 years, most recently at $66.1 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 62.27% year-over-year to $66.1 million; the TTM value through Dec 2025 reached $66.1 million, up 62.27%, while the annual FY2025 figure was $66.1 million, 62.27% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $66.1 million at TransMedics, up from $60.6 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $66.1 million in Q4 2025 and troughed at $9.7 million in Q4 2021.
  • A 5-year average of $35.1 million and a median of $32.6 million in 2024 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: increased 21.28% in 2021 and later surged 99.59% in 2024.
  • Year by year, Accumulated Depreciation & Amortization stood at $9.7 million in 2021, then soared by 34.86% to $13.1 million in 2022, then skyrocketed by 62.18% to $21.3 million in 2023, then surged by 91.21% to $40.7 million in 2024, then soared by 62.27% to $66.1 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for TMDX at $66.1 million in Q4 2025, $60.6 million in Q3 2025, and $53.8 million in Q2 2025.